Evidence map›Paper›PMID 36297584›Full record

ArticlePharmaceutics2022

Development of Multilayer Nanoparticles for the Delivery of Peptide-Based Subunit Vaccine against Group A

Jolynn Kiong, Ummey Jannatun Nahar, Shengbin Jin, Ahmed O Shalash, Jiahui Zhang, Prashamsa Koirala, Zeinab G Khalil, Robert J Capon, Mariusz Skwarczynski, Istvan Toth and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jolynn KiongSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia.
Ummey Jannatun NaharSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia.ORCID 0000-0002-3982-6016
Shengbin JinSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia.ORCID 0000-0002-8108-4626
Ahmed O ShalashSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia.ORCID 0000-0003-3819-4798
Jiahui ZhangSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia.ORCID 0000-0001-7905-2900
Prashamsa KoiralaSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia.ORCID 0000-0003-4436-364X
Zeinab G KhalilInstitute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia.ORCID 0000-0002-9285-1720
Robert J CaponInstitute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia.ORCID 0000-0002-8341-7754
Mariusz SkwarczynskiSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia.ORCID 0000-0001-7257-807X
Istvan TothSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia.
Waleed M HusseinSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Brisbane, QLD 4072, Australia.ORCID 0000-0001-5392-1880
The University of Queensland · AU

Funding

National Health and Medical Research Council APP1132975
6 · The paper itself

Abstract

Peptide-based subunit vaccines include only minimal antigenic determinants, and, therefore, are less likely to induce allergic immune responses and adverse effects compared to traditional vaccines. However, peptides are weakly immunogenic and susceptible to enzymatic degradation when administered on their own. Hence, we designed polyelectrolyte complex (PEC)-based delivery systems to protect peptide antigens from degradation and improve immunogenicity. Lipopeptide (LCP-1) bearing J8 B-cell epitope derived from Group A

Indexed as

cationic polymersdelivery systemsGroup A Streptococcuspeptide vaccinepolyelectrolyte complexespolylysine

Identifiers

PMID36297584
PMCPMC9610843
OpenAlexW4304165588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.